Yu, Lewis
Wu, Nancy
Choi, Okmi
Nguyen, Khoa Dinh
Funding for this research was provided by:
American Parkinson’s Disease Association
SPARK Drug Development Program, Stanford University
Hsiao Fund
Article History
Received: 1 December 2023
Revised: 18 July 2024
Accepted: 13 August 2024
First Online: 21 August 2024
Declarations
:
: All studies were conducted under Laboratory Animal Care (APLAC)-approved protocols.
: All authors have read and approved the manuscript for publication.
: KDN founded and holds equity in Tranquis Therapeutics, a company that develops treatments for neuroinflammatory diseases. Tranquis did not provide funding for these studies. All other authors declared no competing interest.